Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -468.37% is 39% above its 1-year average of -767.72%, near the high end of its 1-year range (-1716.17%–-118.63%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-06-30): -468.37%.
EBITDA MARGIN
-468.37%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$79.46M
EBITDA Margin
-128297.25%
TTM Avg
-89238.38%
3Y Avg
-49477.43%
5Y Avg
-36037.89%
Market Cap
$83.96M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.00M
EBITDA Margin
-4911.29%
TTM Avg
-4911.29%
3Y Avg
-4895.51%
5Y Avg
-4835.22%
Market Cap
$84.70M
EBITDA Margin
31.45%
TTM Avg
-14.67%
3Y Avg
-906.21%
5Y Avg
-1050.55%
Market Cap
$84.75M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$87.86M
EBITDA Margin
-8103.88%
TTM Avg
-7583.93%
3Y Avg
-8667.05%
5Y Avg
-7944.60%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Oncology, Inc. (CTOR) | $81.22M | -468.37% | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $79.46M | -128297.25% | -89238.38% | -49477.43% | -36037.89% |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.00M | -4911.29% | -4911.29% | -4895.51% | -4835.22% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | 31.45% | -14.67% | -906.21% | -1050.55% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.69M | 23.63% | 23.21% | 8.97% | 9.09% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -8103.88% | -7583.93% | -8667.05% | -7944.60% |
| Hyperfine, Inc. (HYPR)vs › | $74.35M | -257.20% | -292.35% | -520.13% | -2376.66% |
Gross Margin
0.0%
EBITDA Margin
-468.4%
Operating Margin
0.0%
Net Margin
-648.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -468.37% |
| 2026-03-31 | -1716.17% |
| 2025-12-31 | -118.63% |
